These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 19525473)
1. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. Niu G; Li Z; Xie J; Le QT; Chen X J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473 [TBL] [Abstract][Full Text] [Related]
2. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534 [TBL] [Abstract][Full Text] [Related]
3. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]
4. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654 [TBL] [Abstract][Full Text] [Related]
6. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487 [TBL] [Abstract][Full Text] [Related]
7. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609 [TBL] [Abstract][Full Text] [Related]
8. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621 [TBL] [Abstract][Full Text] [Related]
9. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685 [TBL] [Abstract][Full Text] [Related]
11. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Chang AJ; De Silva RA; Lapi SE Mol Imaging; 2013; 12(1):17-27. PubMed ID: 23348788 [TBL] [Abstract][Full Text] [Related]
12. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas. Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921 [TBL] [Abstract][Full Text] [Related]
13. Cumulated Activity Comparison of Laffon E; Thumerel M; Jougon J; Marthan R J Nucl Med; 2017 Jun; 58(6):888-890. PubMed ID: 28082435 [TBL] [Abstract][Full Text] [Related]
14. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484 [TBL] [Abstract][Full Text] [Related]
15. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Cai W; Chen K; He L; Cao Q; Koong A; Chen X Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214 [TBL] [Abstract][Full Text] [Related]
17. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350 [TBL] [Abstract][Full Text] [Related]